Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.35 -6.8%	$0.39	$0.30 ▼ $10.62	$50.12M	1.86	3.37 million shs	1.02 million shs
AVTE Aerovate Therapeutics	$6.99 +3.4%	$32.04	$43.75 ▼ $105.00	$202.61M	0.95	16,012 shs	327,062 shs
FDMT 4D Molecular Therapeutics	$4.15 -5.0%	$3.51	$2.24 ▼ $28.93	$203.37M	2.84	828,280 shs	259,911 shs
KOD Kodiak Sciences	$3.55 -5.1%	$3.65	$1.92 ▼ $11.60	$204.72M	2.27	348,091 shs	243,169 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	-6.81%	-10.64%	-42.78%	-32.29%	-92.86%
AVTE Aerovate Therapeutics	+3.40%	-9.34%	-4.83%	-92.07%	-87.90%
FDMT 4D Molecular Therapeutics	-5.03%	-7.16%	+20.64%	+9.50%	-82.56%
KOD Kodiak Sciences	-5.08%	-15.88%	+1.43%	+5.97%	+31.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.0378 of 5 stars	3.3	3.0	4.7	1.9	1.7	0.6
AVTE Aerovate Therapeutics	1.7667 of 5 stars	3.0	0.0	0.0	2.3	1.7	0.6
FDMT 4D Molecular Therapeutics	2.5587 of 5 stars	3.3	3.0	0.0	2.8	1.7	0.6
KOD Kodiak Sciences	4.3572 of 5 stars	3.0	4.0	4.6	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,668.12% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	612.18% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	153.52% Upside

Current Analyst Ratings Breakdown

Latest APLT, KOD, FDMT, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/31/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/22/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$460K	106.19	N/A	N/A	$0.49 per share	0.70
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	4,806.74	N/A	N/A	$11.05 per share	0.38
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/14/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)

Latest APLT, KOD, FDMT, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
4/14/2025	Q4 2024	APLT Applied Therapeutics	-$0.18	-$0.24	-$0.06	$0.33	$0.61 million	$0.00 million
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Latest APLT, KOD, FDMT, and AVTE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	1.06	1.06
AVTE Aerovate Therapeutics	N/A	8.78	8.78
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
KOD Kodiak Sciences	N/A	8.42	8.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
AVTE Aerovate Therapeutics	N/A
FDMT 4D Molecular Therapeutics	99.27%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
AVTE Aerovate Therapeutics	24.90%
FDMT 4D Molecular Therapeutics	9.60%
KOD Kodiak Sciences	45.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable

APLT, KOD, FDMT, and AVTE Headlines

Recent News About These Companies

Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update

June 17 at 9:55 AM | marketbeat.com

Bank of America Corp DE Has $169,000 Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

June 16 at 3:01 AM | marketbeat.com

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

June 13, 2025 | zacks.com

Trump’s cuts to fisheries science have industry and conservation groups sounding alarm

June 11, 2025 | kucb.org

Alaska Aerospace, UAF to partner on new space ventures

June 11, 2025 | kodiakdailymirror.com

Q2 EPS Estimates for Kodiak Sciences Cut by Zacks Research

June 8, 2025 | americanbankingnews.com

Q2 EPS Forecast for Kodiak Sciences Reduced by Analyst

June 6, 2025 | marketbeat.com

Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

June 5, 2025 | theglobeandmail.com

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | prnewswire.com

Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads

May 29, 2025 | investing.com

Kodiak Sciences Q2 EPS Forecast Decreased by HC Wainwright

May 23, 2025 | marketbeat.com

Point72 Asset Management L.P. Buys New Shares in Kodiak Sciences Inc. (NASDAQ:KOD)

May 22, 2025 | marketbeat.com

Kodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 15, 2025 | finanznachrichten.de

Kodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss

May 15, 2025 | marketwatch.com

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

May 15, 2025 | zacks.com

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 14, 2025 | prnewswire.com

Why Kodiak Sciences Inc.’s (KOD) Stock Is Down 15.35%

May 7, 2025 | aaii.com

BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc.

May 6, 2025 | gurufocus.com

More companies announce ARVO 2025 presentations

May 2, 2025 | ophthalmologytimes.com

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

May 1, 2025 | prnewswire.com

Seismologists monitoring string of Kodiak-area quakes

April 29, 2025 | alaskapublic.org

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT, KOD, FDMT, and AVTE Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.34 -0.03 (-6.81%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$0.35 +0.01 (+2.61%)

As of 04:39 AM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Aerovate Therapeutics NASDAQ:AVTE

$6.99 +0.23 (+3.40%)

As of 06/16/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$4.15 -0.22 (-5.03%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$4.17 +0.02 (+0.48%)

As of 06/17/2025 05:44 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Kodiak Sciences NASDAQ:KOD

$3.55 -0.19 (-5.08%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$3.72 +0.17 (+4.79%)

As of 06/17/2025 04:43 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time